340B program

Lawmakers are urging the U.S. Department of Health and Human Services to force Eli Lilly to reinstate 340B drug discounts to hospitals. The company stopped offering discounts to 50 hospital systems that failed to comply with a new policy requiring claims data sharing. Lawmakers argue Lilly's actions violate federal law by eliminating mandated price breaks.

The Trump administration proposes a rule to prevent hospitals from charging markups on discounted drugs for Medicare patients, aiming to save $1.1 billion annually. Former CIA Director John Brennan sued the administration over record preservation, while an FBI agent in Chicago resigned amid workforce changes under Director Kash Patel. The American Hospital Association warned the rule could harm hospitals' financial stability.

The Trump administration proposes a rule to prevent hospitals in the 340B program from charging markups on discounted drugs for Medicare patients, estimating $1.1 billion in annual savings. The rule aims to change reimbursement formulas to reduce patient costs, but the American Hospital Association warns it could strain hospital finances and access to care.

The Trump administration is proposing a rule to prevent hospitals in the 340B program from billing insurers above discounted drug costs for Medicare patients, aiming to save $1.1 billion annually. The rule targets hospitals that currently markup drug prices, which could reduce patient costs but may also impact hospital revenues and services.

The Trump administration proposes a rule to prevent hospitals in the 340B program from charging markups on discounted drugs for Medicare patients, aiming to save $1.1 billion annually. The rule would reduce Medicare reimbursements for these hospitals by approximately 40%, targeting cost savings for patients while raising concerns about potential revenue losses for hospital systems.

The Trump administration proposes a rule to prevent hospitals in the 340B program from charging markups on discounted drugs for Medicare patients, aiming to save $1.1 billion annually. The rule would adjust Medicare reimbursement formulas for these hospitals, with an example showing potential savings on the prostate cancer drug Lupron Depot.

An Eighth Circuit panel denied Novartis Pharmaceuticals' request to block Missouri's Senate Bill 751, which requires drugmakers to provide discounted 340B program drugs to eligible providers. The court ruled the law does not violate the dormant commerce clause as it regulates only in-state delivery of drugs to contract pharmacies.